Person:
Jain, Supriya Rani

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Jain

First Name

Supriya Rani

Name

Jain, Supriya Rani

Filters

20081

Settings

Author's Publications: search.filters.isAuthorOfPublication.53e9762c-867e-4cdd-b394-c4aef01fc438

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Publication
    CDK8 Is a Colorectal Cancer Oncogene That Regulates β-Catenin Activity
    (Springer Nature, 2008) Firestein, Ron; Bass, Adam; Kim, So Young; Dunn, Ian; Silver, Serena J.; Guney, Isil; Freed, Ellen; Ligon, Azra; Vena, Natalie; Ogino, Shuji; Chheda, Milan; Tamayo, Pablo; Finn, Stephen; Shrestha, Yashaswi; Boehm, Jesse S.; Jain, Supriya Rani; Bojarski, Emeric; Mermel, Craig; Barretina, Jordi; Chan, Jennifer; Baselga, Jose; Tabernero, Josep; Root, David E.; Fuchs, Charles; Loda, Massimo; Shivdasani, Ramesh; Meyerson, Matthew; Hahn, William
    Aberrant activation of the canonical Wnt/β-catenin pathway occurs in almost all colorectal cancers and contributes to their growth, invasion and survival. Although dysregulated β-catenin activity drives colon tumorigenesis, additional genetic perturbations are required to elaborate fully malignant disease. To identify genes that both modulate β-catenin activity and are essential for colon cancer cell proliferation, we conducted two loss-of-function screens in human colon cancer cells and compared genes identified in these screens with an analysis of copy-number alterations in colon cancer specimens. One of these genes, CDK8, which encodes a member of the mediator complex, is located at 13q12.13, a region of recurrent copy number gain in a substantial fraction of colon cancers. Suppression of CDK8 expression inhibited proliferation in colon cancer cells characterized by high levels of CDK8 and β-catenin hyperactivity. CDK8 kinase activity was necessary for β-catenin driven transformation and expression of several β-catenin transcriptional targets. Together these observations suggest that therapeutic interventions targeting CDK8 may confer clinical benefit in β-catenin-driven malignancies.